Plasma levels of JC virus are sensitive and specific for detecting and predicting progressive multifocal leukoencephalopathy in HIV patients

Future Virology

Volumn 7, Issue 8, 2012, Pages 833-839

  Bayliss, Julianne ^a,b   Cherry, Catherine L ^a,c,d   McLean, Catriona A ^a,d  

^a MONASH UNIVERSITY   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c BURNET INSTITUTE   (Australia)

^d ALFRED HOSPITAL   (Australia)

Author keywords

HIV; JC virus; PCR; progressive multifocal leukoencephalopathy; sensitivity; specificity

Indexed keywords

VIRUS DNA; VIRUS LARGE T ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; JC VIRUS; MALE; NESTED POLYMERASE CHAIN REACTION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS 1; JC POLYOMAVIRUS;

EID: 84865484376     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.70     Document Type: Article

References (28)

1. Linda H, Von Heijne A, Major EO et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N. Engl. J. Med. 361(11), 1081-1087 (2009).
2. Hartung H-P. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol. 8(1), 28-31 (2009).
3. Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab the University of North Carolina at Chapel Hill. Arthritis Rheum. 62(11), 3191-3195 (2010).
4. Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354(9), 924-933 (2006).
5. Yorita Christensen KL, Holman RC, Hammett TA, Belay ED, Schonberger LB. Progressive multifocal leukoencephalopathy deaths in the USA, 1979-2005. Neuroepidemiology 35(3), 178-184 (2010).
6. Khanna N, Elzi L, Mueller NJ et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin. Infect. Dis. 48(10), 1459-1466 (2009).
7. Drake AK, Loy CT, Brew BJ et al. Human immunodeficiency virus-associated progressive multifocal leucoencephalopathy: Epidemiology and predictive factors for prolonged survival. Eur. J. Neurol. 14(4), 418-423 (2007). (Pubitemid 46481167)
8. Engsig FN, Hansen AB, Omland LH et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: A nationwide cohort study. J. Infect. Dis. 199(1), 77-83 (2009).
9. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis. Lancet Neurol. 9(4), 425-437 (2010).
10. Ikegaya H, Iwase H, Zheng H-Y et al. JC virus genotyping using formalin-fixed, paraffin-embedded renal tissues. J. Virol. Methods 126(1-2), 37-43 (2005). (Pubitemid 40558741)
11. Tan CS, Ellis LC, Wuthrich C et al. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J. Virol. 84(18), 9200-9209 (2010).
12. Bayliss J, Karasoulos T, Bowden S, Glogowski I, Mclean CA. Immunosuppression increases latent infection of brain by JC polyomavirus. Pathology 43(4), 362-367 (2011).
13. Maginnis MS, Atwood WJ. JC Virus: An oncogenic virus in animals and humans? Semin. Cancer Biol. 19(4), 261-269 (2009).
14. Bayliss J, Moser R, Bowden S, Mclean CA. Characterisation of single nucleotide polymorphisms in the genome of JC polyomavirus using MALDI TOF mass spectrometry. J. Virol. Methods 164(1-2), 63-67 (2010).
15. Müller R, Büttner P. A critical discussion of intraclass correlation coefficients. Stat. Med. 13(23-24), 2465-2476 (1994).
16. Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 52(2), 253-260 (1999). (Pubitemid 29059048)
17. Dubois V, Moret H, Lafon ME et al. Prevalence of JC virus viraemia in HIV-infected patients with or without neurological disorders: A prospective study. J. Neurovirol. 4(5), 539-544 (1998). (Pubitemid 28499349)
18. Dubois V, Dutronc H, Lafon ME et al. Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J. Clin. Microbiol. 35(9), 2288-2292 (1997). (Pubitemid 27349798)
19. Rudick RA, O'Connor PW, Polman CH et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann. Neurol. 68(3), 304-310 (2010).
20. Viscidi RP, Khanna N, Tan CS et al. John Cunningham virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin. Infect. Dis. 53(7), 711-715 (2011).
21. Berger Jr. Progressive multifocal leukoencephalopathy. Curr. Neurol. Neurosci. Rep. 7(6), 461-469 (2007). (Pubitemid 350090305)
22. Chen Y, Bord E, Tompkins T et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med. 361(11), 1067-1074 (2009).
23. Jilek S, Jaquiéry E, Hirsch HH et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: A cross-sectional and longitudinal study. Lancet Neurol. 9(3), 264-272 (2010).
24. Reid C.E, Li H, Sur G et al. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J. Infect. Dis. 204(2), 237-244 (2011).
25. Khanna N, Wolbers M, Mueller NJ et al. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J. Virol. 83(9), 4404-4411 (2009).
26. Shishido-Hara Y. Progressive multifocal leukoencephalopathy and promyelocytic leukemia nuclear bodies: A review of clinical, neuropathological, and virological aspects of JC virus-induced demyelinating disease. Acta Neuropathol. 120(3), 403-417 (2010).
27. Marzocchetti A, Sanguinetti M, Giambenedetto SD et al. Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: Insights into viral pathogenesis and disease prognosis. J. Neurovirol. 13(4), 338-346 (2007). (Pubitemid 47400032)
28. Tan CS, Dezube BJ, Bhargava P et al. Detection of JC virus DNA and proteins in the bone marrow of HIV positive and HIV negative patients: Implications for viral latency and neurotropic transformation. J. Infect. Dis. 199(6), 881-888 (2009).